Iovance Biotherapeutics, Inc.
IOVA
Iovance Biotherapeutics, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cancer immunotherapy products to harness the power of a patient's immune system to eradicate cancer cells. It has six ongoing phase 2 clinical studies, including C-144-01, of its lead product candidate, lifileucel, for the treatment of metastatic melanoma; C-145-04, of its product candiā¦ read more
Healthcare
Biotechnology
15 years
USD
Exclusive to Premium users
Price
per share adjusted in USD$2.30
Price-0.43%
-$0.01
1Y
Price
Market Cap
$832.597m
Small
Price/Earnings 3y Avg5y Avg
-
Premium
Premium
Financials Overview
Key metrics over the past few years-169.9%
EBITDA Margin-186.2%
Net Profit Margin-124.9%
Free Cash Flow MarginRevenue
$241.524m
+47.2%
1y CAGR+4582.1%
3y CAGR+3436.6%
5y CAGREarnings
-$389.921m
-4.8%
1y CAGR-0.2%
3y CAGR-4.1%
5y CAGREPS
-$1.23
+3.9%
1y CAGR+20.1%
3y CAGR+12.2%
5y CAGRBook Value
$698.488m
$907.437m
Assets$208.949m
Liabilities$53.166m
DebtDebt to Assets
5.9%
-0.1x
Debt to EBITDAFree Cash Flow
-$323.538m
+11.1%
1y CAGR-2.1%
3y CAGR-6.1%
5y CAGRFinancial Reports
Earnings and other important metrics. Amounts in USD.No items found.
Press Releases
Statements and updates from the company